Olink’s protein biomarker panel for applications in immuno-oncology and immunotherapy just got better!
Please note that these details apply to the version of the panel with article number 95311, released on June 13, 2019. This replaces the previous version with article number 95310.
With 92 high-quality assays, Olink® Target 96 Immuno-Oncology is the ideal solution for researchers working with immunotherapy and who want to measure proteins relevant for key processes such as tumor immunity, tumor vascular & tissue remodeling, chemotaxis and checkpoint proteins.
While the original version of the Immuno-Oncology panel has been successful, Olink continues to listen to and act upon the feedback we receive from our customers, and we have therefore made a small number of significant improvements to the assay composition and performance of the panel, which are described below.
1) Firstly, we have improved the detectabilty and broader performance of two of the assays from the original version of the panel:
Tumor Necrosis Factor (TNF) Uniprot number P01375 (also known as TNF-alpha)
Interferon-gamma (IFN-gamma) Uniprot number P01579
The performance of both these assays has been greatly improved in terms of significantly enhanced detectability in human plasma, and broader dynamic ranges. During our validation process, the new TNF and IFN-gamma assays both measured signals above LOD in 100% of plasma samples tested (from patients with a range of diseases and healthy subjects). For TNF, the previously used monoclonal antibody has been replaced by a polyclonal antibody, enabling both the monomeric and multimeric forms of the protein to be detected using the PEA technique. In line with other commercial assays and to better meet customers’ needs, the Immuno-oncology panel can now therefore measure all the forms of TNF that may be expected to be present in human samples. These improved assays were recently incorporated into the Olink Inflammation panel, and you can see more information and technical data about these two assays on the information page we published for the launch of the improved Inflammation panel – read more
2) Also based on customer feedback, we have decided to remove three assays that have shown relatively low detectability in a number of studies, and to replace them with alternative, better performing assays for proteins of relevance for immuno-oncology applications. The assays removed are:
Interleukin-21 (IL-21), Uniprot Q9HBE4
Interleukin-35 (IL-35), Uniprot Q14213/ P29459
Interferon beta (IFN-beta), Uniprot P01574
These have now been replaced by the following assays:
Lymphocyte activation gene 3 protein (LAG3), Uniprot P18627. Interleukin-15 (IL15), Uniprot P40933.
These two proteins are checkpoint immune receptors, and promising candidates for cancer immunotherapy..
Mucin-16 (MUC-16), Uniprot Q8WXI7.
Also known as CA-125, this protein is a suppressor of tumor immunity and a well-known biomarker for ovarian cancer that is used to monitor patients during treatment.
3) Finally, we have replaced the assay for Vascular endothelial growth factor C (VEGFC), Uniprot P49767 with Killer cell immunoglobulin-like receptor 3DL1 (KIR3DL1), Uniprot P43629. The replacement assay is highly relevant for the Immuno-Oncology panel, since KIR3DL1 is a known immune checkpoint receptor.
Please note: Although all of the replacement assays listed above were subject to rigorous validation & QC during their development, final validation data in full-panel context is not yet available. This will be updated as soon as possible.
All of the replacement assays listed above are available in other Olink panels, and with these changes, Olink® IMMUNO-ONCOLOGY can now be considered as a complete “overlap” panel (i.e. all assays are available in other panels) that is dedicated for applications in the immuno-oncology/immunotherapy area. This panel is the ideal choice for researchers looking for protein biomarkers to help their studies in immuno-oncology. For the full protein list, functional categorization and other information, visit the Immuno-oncology panel page.